> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pediatric Oncology Panel 2-Day Meeting
- URL: https://www.fdaweb.com/pediatric-oncology-panel-2-day-meeting/
- Published: 2021-04-13T12:00:00.000Z
- Updated: 2026-09-14T16:54:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149094

*Federal Register* notice: FDA has announced a 5/11-12 Oncologic Drugs Advisory Committee’s Pediatric Oncology Subcommittee meeting. On 5/11, the subcommittee will discuss the development and successful implementation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events as a tool for capturing the patient’s voice in oncology clinical trials to more accurately determine tolerability and toxicity of drugs under investigation. On 5/12, the panel will discuss real-world evidence (RWE) for regulatory use in pediatrics, real-world data (RWD) resources, and RWD and RWE to advance pediatric safety assessments of oncology drug products in children within the context of the FDA framework for RWE. Potential data sources and publicly available platforms, including those made possible through the development and implementation of the National Cancer Institute’s Childhood Cancer Data Initiative, will be discussed. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-13/pdf/2021-07546.pdf?ref=fdaweb.com).